SCHEMBL35211487

SCHEMBL35211487

O[C@@H]1CCc2c1ccc(F)c2Br

nearest known ligand 0.37

Predicted protein targets (top 15)

geneUniProtsupporting neighboursconfidence
CYP11B1 P15538 4/20 0.37
CYP11B2 P19099 4/20 0.37
NR3C2 P08235 1/20 0.34
DRD2 P14416 1/20 0.32
DRD3 P35462 1/20 0.32
POLL Q9UGP5 1/20 0.31
MAP3K14 Q99558 1/20 0.31
EPAS1 Q99814 1/20 0.30
CYP19A1 P11511 1/20 0.30
STS P08842 1/20 0.30
S1PR1 P21453 3/20 0.30
S1PR2 O95136 1/20 0.30
S1PR4 O95977 1/20 0.30
S1PR3 Q99500 1/20 0.30
S1PR5 Q9H228 1/20 0.30

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL15021555 1.00 CYP11B1 (0.37) CYP11B1CYP11B2NR3C2DRD2DRD3
SCHEMBL15287108 1.00 CYP11B1 (0.37) CYP11B1CYP11B2NR3C2DRD2DRD3
SCHEMBL9274574 0.81 CYP11B1 (0.38) CYP11B1CYP11B2NR3C2DRD2DRD3
SCHEMBL18101342 0.78 CYP11B1 (0.37) CYP11B1CYP11B2NR3C2S1PR1S1PR2
SCHEMBL18094370 0.78 KDM1A (0.41) CYP11B1CYP11B2NR3C2POLLEPAS1
SCHEMBL16798270 0.78 KDM1A (0.41) CYP11B1CYP11B2NR3C2POLLEPAS1
SCHEMBL15287132 0.78 MAP3K14 (0.34) CYP11B1CYP11B2POLLMAP3K14STS
SCHEMBL9282806 0.78 HTR2A (0.40) CYP11B1CYP11B2NR3C2DRD2DRD3
SCHEMBL15286837 0.77 CYP11B1 (0.45) CYP11B1CYP11B2NR3C2S1PR1
SCHEMBL1154471 0.77 DRD2 (0.44) CYP11B1CYP11B2NR3C2DRD2DRD3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260125359-A1 HETEROARYL COMPOUNDS AS MULTI-TARGET PROTEIN KINASE INHIBITORS FUJIAN HAIXI PHARMACEUTICALS CO LTD (CN) 2026-05-07 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260125359-A1 HETEROARYL COMPOUNDS AS MULTI-TARGET PROTEIN KINASE INHIBITORS ERBB2, ERBB3, ARRB1 CYP11B1 644/4885CYP11B2 918/4885NR3C2 16/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.